NL-OMON34177已完成2 期
Betablocker Therapy in Pulmonary Arterial Hypertension - *-blocker in iPAH
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Idiopathic PAH patients
- •Stable on PAH specific treatment defined
- •No change in PAH specific treatment in the past 6 months
- •No change in functional class in the past 6 months
- •<10 % change in 6 minute walk distance in the past 6 months
- •Functional class 2 or 3
- •In sinus rhythm
排除标准
- •History of systemic hypertension, ischaemic heart disease, valvular disease or cardiomyopathy.
- •Use of concomitant medication other than diuretics, acenocoumarol and PAH targeted therapy
- •History of cardiac arrhythmias or the use of anti-arrhythmic drugs
- •Sick sinus syndrome
- •Systolic hypotension < 90 mmHg
- •Clinically relevant sinus-bradycardia
研究者
相似试验
进行中（未招募）
不适用
Betablocker Therapy in Pulmonary Arterial HypertensioEUCTR2010-020424-21-NLVU medical center
进行中（未招募）
1 期
Racecadotril used in combination with sildenafil to reduce blood pressure in the lungs.Pulmonary hypertensionMedDRA version: 14.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-003921-13-GBniversity College London21
招募中
2 期
Bosentan and Sildenafil in Pulmonary Hypertension in Cardiac AnesthesiaPACTR202209903019732Mansoura university40
终止
1 期
Carvedilol PAH A Pilot Study of Efficacy and SafetyCardiac MRI <40Pulmonary HypertensionNCT02120339University of Minnesota5
终止
2 期
Beta-blockers in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT02507011University of Minnesota2